RNA theranostics in cancer

RNA theranostics is emerging as a transformative approach in oncology, offering powerful opportunities for both cancer diagnosis and precision treatment. Recent advances in nanomedicine and biomaterials have enabled the design of sophisticated RNA-based platforms, including mRNA, siRNA, and other functional RNA systems, with improved delivery efficiency, biological stability, and tumor selectivity.This presentation will highlight recent progress in RNA theranostics for cancer, focusing on nanotechnology-enabled RNA delivery systems and biomaterial-based platforms for tumor-targeted therapy and cancer immunotherapy. Particular attention will be given to how these strategies can overcome key barriers in oncology, such as inefficient delivery, off-target effects, immune-related challenges, and limited translational applicability. The integration of RNA engineering with nanomedicine holds great promise for advancing precision oncology and accelerating the development of next-generation cancer therapeutics.

Dr. Shuying Chen is an associate professor at Huashan Hospital, Fudan University, Shanghai, China. Her work focuses on nanomedicine, RNA therapeutics, cancer immunotherapy, and translational oncology, with particular expertise in biomaterial-based RNA delivery systems, tumor-targeted therapy, and cancer theranostics. Her research aims to bridge advanced biomaterials, RNA technology, and clinical oncology to develop next-generation strategies for precision cancer diagnosis and treatment.